 Emmaus Life Sciences Inc OTCQX:EMMA said it has partnered with UpScript IP Holdings LLC, to offer telehealth solutions to sickle cell disease patients, expanding access to Endari, Emmaus prescription L-glutamine oral powder for the treatment of the disease. The Torrance, California-based company said the telehealth partnership with UpScript will allow patients to see a doctor without leaving home, eliminating the risk of infection that can occur with hospital visits. 